Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank62
3Y CAGR+12.7%
5Y CAGR-49.6%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+12.7%/yr
Quarterly compound
5Y CAGR
-49.6%/yr
Recent acceleration
Percentile
P62
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 23.94% |
| Q3 2025 | 78.88% |
| Q2 2025 | -35.96% |
| Q1 2025 | -12.62% |
| Q4 2024 | 54.06% |
| Q3 2024 | 113.97% |
| Q2 2024 | -57.73% |
| Q1 2024 | 26.19% |
| Q4 2023 | -22.95% |
| Q3 2023 | 89.10% |
| Q2 2023 | -9.42% |
| Q1 2023 | -5.64% |
| Q4 2022 | 16.73% |
| Q3 2022 | 74.81% |
| Q2 2022 | -17.02% |
| Q1 2022 | -42.56% |
| Q4 2021 | -32.07% |
| Q3 2021 | 233.49% |
| Q2 2021 | -37.35% |
| Q1 2021 | 17.89% |
| Q4 2020 | 733.12% |
| Q3 2020 | 112.59% |
| Q2 2020 | 156.05% |
| Q1 2020 | 81.82% |
| Q4 2019 | 11.16% |
| Q3 2019 | -17.35% |
| Q2 2019 | -388.77% |
| Q1 2019 | -172.42% |
| Q4 2018 | 138.36% |
| Q3 2018 | 0.08% |
| Q2 2018 | 16.25% |
| Q1 2018 | -115.10% |
| Q4 2017 | 658.23% |
| Q3 2017 | 216.67% |
| Q2 2017 | 23.64% |
| Q1 2017 | -39.13% |
| Q4 2016 | -76.78% |
| Q3 2016 | 34.54% |
| Q2 2016 | 0.78% |
| Q1 2016 | 16.10% |